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The purpose of this study was to examine the appearance
and activation of collagenase-1 (MMP-1) in the wound
environment. We found that MMP-1 accumulates in the
fluid phase of the burn wound environment within 2 d
of injury and reaches maximal levels by day 4. Two
forms of the enzyme were evident; one that corresponded
to proMMP-1 and another that corresponded to a group
of high molecular mass (µ200 kDa and >200 kDa doublet)
MMP-1 containing complexes. ProMMP-1 and MMP-1
containing complexes also occurred in wound fluid from
venous stasis ulcers, but neither was detected in mastec-
Wound healing is a coordinated process involvingtissue degradation and regeneration. Since theearly studies of Grillo and Gross (1967) on colla-genase, there has been considerable interest in theproteolytic enzymes that act within the wound
environment and their regulation.
Collagenase and other enzymes can be detected in human inflam-
matory fluids, as was first shown by Harris et al (1969) in research on
synovial fluid. Recently, we and others have used wound fluid to
identify the proteinases present during wound repair (Wysocki and
Grinnell, 1990; Kirsner et al, 1993; Tarnuzzer and Schultz, 1996).
Wound fluid contains a mixture of plasma components, including the
adhesion proteins fibronectin and vitronectin (Grinnell et al, 1992),
proteinases (see below), and growth factors (Alper et al, 1985; Matsuoka
and Grotendorst, 1989; Cooper et al, 1994).
A wide array of proteinases have been identified in wound fluid.
These include matrix metalloproteinases (Chen et al, 1992a; Agren
et al, 1992; Young and Grinnell, 1994) and serine proteinases (Palolahti
et al, 1993; Stacey et al, 1993; He et al, 1998). Gelatinases occur at
particularly high levels in wound fluid from chronic leg ulcers (Wysocki
et al, 1993; Bullen et al, 1995; Yager et al, 1996; Weckroth et al, 1996),
and elastase has been identified as the enzyme in wound fluid responsible
for fibronectin degradation (Grinnell and Zhu, 1994, 1996; Rao et al,
1995). It has been suggested that excessive destruction of extracellular
matrix molecules by proteinases may be a contributing factor in chronic
wounds (Falanga et al, 1994). Similarly, elevated proteinase levels have
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tomy fluid or in plasma. Levels of the proteinase inhibitor
a2-macroglobulin in burn fluid and chronic ulcer wound
fluid were almost as high as in plasma, and the high
molecular mass MMP-1 containing complexes in burn
fluid appeared to result from binding between a2-macro-
globulin and activated MMP-1. These observations pro-
vide direct evidence that active MMP-1 in the fluid phase
of the wound environment becomes complexed to a2-
macroglobulin. Key words: metalloproteinase/TIMP/wound
repair. J Invest Dermatol 110:771–776, 1998
been implicated in persistent inflammatory conditions such as bullous
skin diseases (Oikarinen et al, 1983, 1993; Jensen et al, 1988; Lauharanta
et al, 1989), arthritic joints (Al-Haik et al, 1984; Cawston et al, 1987;
Partsch et al, 1994), and periodontal disease (Sodek and Overall, 1992;
Lee et al, 1995). Recent experiments suggest that such elevated levels
may result from a lack of soluble inhibitors rather than overproduction
of the enzymes (Bullen et al, 1995; Vaalamo et al, 1996).
Experiments using immunolocalization and in situ hybridization
have established that collagenase-1 (MMP-1), the enzyme primarily
responsible for digestion of native type I collagen, is expressed in
cutaneous wounds during active periods of epithelization (Saarialho-
Kere et al, 1993, 1995; Inoue et al, 1995; Vaalamo et al, 1996). Synthesis
of the enzyme has been detected by day 2 in migrating keratinocytes
(Saarialho-Kere et al, 1995), and MMP-1 also appears to be produced
by stromal cells (Porras-Reyes et al, 1991; Girard et al, 1993; Stricklin
et al, 1994; Stricklin and Nanney 1994). These visualization methods
do not reveal enzyme activity, but other studies have shown that low
levels of an enzyme capable of degrading radiolabeled type I collagen
can be detected in acute and chronic wound fluids (Yager et al, 1996;
Weckroth et al, 1996).
Previously, using a longitudinally collected series of burn fluid
samples, we characterized a gelatinase secretion/activation cascade that
occurred at 2–4 d following injury (Young and Grinnell, 1994). In
this study, similar studies were carried out using antibodies against
MMP-1. We found that MMP-1 appeared in wound fluid around day
2 after injury, but was mostly in the form of high molecular mass
complexes (µ200 kDa and >200 kDa doublet). The >200 kDa doublet
complexes were also detected in wound fluid from venous stasis ulcers.
Burn fluid and chronic wound contained α2-macroglobulin (α2M) at
levels similar to those found in plasma, and α2M appeared to be
responsible for the formation of the high molecular mass complexes
with activated MMP-1.
MATERIALS AND METHODS
Materials Human plasma fibronectin was obtained from the New York
Blood Center (New York, NY). Human α2M was purchased from ICN
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Biochemicals (Aurora, OH). Mouse-anti-TIMP-1 and mouse anti-collagenase
(MMP-1) were purchased from Calbiochem (Cambridge, MA). Rabbit anti-
α2M was purchased from Sigma (St. Louis, MO). Alkaline phosphatase
conjugated goat anti-rabbit IgG and goat anti-mouse IgG were purchased from
Bio-Rad (Richmond, CA). Protein A Sepharose CL-4B was purchased from
Pharmacia Biotech (Piscataway, NJ).
Wound fluid and serum This research project was approved by the
University Institutional Review Board. Informed consent was obtained for all
procedures. Samples of mastectomy fluid were obtained from three patients
following mastectomy operations. Fluid was harvested from fluid collection
devices (HemoVac and ConstaVac) in sterile test tubes at 24 and 48 h after
surgery. Collection periods lasted about 4 h. Samples of burn fluid were from
three patients whose burn wounds included an extremity. Sampling of burn
fluid was initiated 4–8 h after injury (day 0) and continued at 48–72 h intervals.
Collections were carried out over 4 h periods during which time patient
extremities were enclosed in a sterile glove and held in place with a non-
compressive cling wrap. Samples of venous stasis ulcer wound fluid were at
µ1 wk intervals over 3 wk periods from five patients with venus stasis ulcers.
Each fluid collection period lasted for 4 h. During this time, wound fluid
accumulated beneath a transparent film dressing. Wound fluid was harvested
using a sterile tuberculin syringe equipped with a 20 gauge stainless steel needle,
being careful to avoid injury to the underlying granulation tissue. Wound fluid
samples were centrifuged at 22,000 3 g (Beckman J2–21 M, 20 rotor) for
15 min at 22°C.
Blood samples were obtained by venipuncture from normal volunteers. To
prepare plasma, cells were removed by centrifugation (1800 3 g for 15 min at
22°C followed by 22,000 3 g for 30 min at 4°C). To prepare serum, CaCl2
was added to the plasma at a final concentration of 20 mM. After 2 h at 37°C,
serum was clarified by centrifugation as above. Wound fluid supernatants,
plasma, and serum samples were frozen in liquid N2 and stored at –70°C until use.
Preparation and activation of MMP-1 containing fibroblast culture
supernatant Human foreskin fibroblasts were cultured up to seven passages
in Dulbecco’s minimal essential medium (Gibco, Grand Island, NY) containing
10% fetal bovine serum (Intergen, Newark, NJ) in a humidified incubator with
5% CO2. Cells from preconfluent cultures were harvested with 0.25% trypsin/
0.1 mM ethylenediamine tetraacetic acid (Gibco), and trypsin was neutralized
with fetal bovine serum (1:1 vol/vol). Cell aliquots (105) in 1.0 ml medium
were cultured in 12 well culture plates for 2 d and switched to 0.3 ml
serum-free Dulbecco’s minimal essential medium containing 100 nM 12-o-
tetradecanoylphorbol-13-acetate (Sigma) to induce synthesis and secretion of
collagenase (proMMP-1) (Aggeler et al, 1984). After 24 h, culture supernatants
were collected and stored at –20°C. Activation of proMMP-1 to MMP-1 by
treatment with mercurials (Stricklin et al, 1983) was accomplished using 4 mM
p-aminophenylmercuric acetate (APMA) at 37°C for the times indicated in the
figure legends.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting SDS-PAGE and immunoblotting were carried
out as described previously (Young and Grinnell, 1994; Grinnell and Zhu,
1994). Briefly, samples for SDS-PAGE were dissolved in reducing sample buffer
[62.5 mM Tris, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 0.01%
bromophenol blue, pH 6.8, 5% mercaptoethanol] unless indicated otherwise
and subjected to electrophoresis on 7.5% acrylamide mini-gels (Bio-Rad Mini-
Protean apparatus) at 22°C and 200 V for 45 min. Bio-Rad high molecular
mass standards were used for markers.
For immunoblotting, polypeptides separated by SDS-PAGE were transferred
to nitrocellulose paper (Schleicher & Schuell) by electrophoresis at 22°C for
1 h at 100 V or at 22°C for 16 h at 34 V. The transferred proteins were
incubated with primary antibodies for 2 h at 22°C followed by incubation
with alkaline phosphatase-conjugated secondary antibodies for 1 h at 22°C.
Visualization was accomplished using the Bio-Rad alkaline phosphatase conju-
gate substrate kit according to the manufacturer’s instructions.
RESULTS
Burn fluid and chronic wound fluid contain high molecular
mass MMP-1 complexes Immunoblotting analysis of MMP-1 in
burn fluid samples collected from three patients is shown in Fig 1.
No MMP-1 was detected in the earliest samples of burn fluid (0 5
day 0, about 4–6 h post-injury). As early as day 2 post-injury, however,
we observed a single MMP-1 band in burn fluid that migrated slightly
faster than the nonspecific IgG heavy chain band and corresponded to
proMMP-1. The intensity of proMMP-1 peaked at day 4 and declined
thereafter. Beginning on day 4, burn fluid also contained several high
molecular mass bands (*MMP-1) that were detected by the anti-
Figure 1. Burn fluid contains a mixture of MMP-1 and covalently cross-
linked MMP-1 complexes (*MMP-1). Samples of fibroblast conditioned
medium (CM, 20 µl), mastectomy fluid (MF, 75 µg), and burn fluid (BF,
75 µg) from three different patients on the days indicated following injury,
were subjected to SDS-PAGE and immunoblotted with antibodies against
MMP-1.
Figure 2. Chronic wound fluid from venous stasis ulcers contains MMP-
1 and MMP-1 complexes. Samples of fibroblast conditioned medium (CM,
20 µl), mastectomy fluid (MF, 75 µg), and chronic wound fluid (CF, 75 µg)
collected from five different patients at weekly intervals as indicated, were
subjected to SDS-PAGE and immunoblotted with antibodies against MMP-1.
MMP-1 antibody. The precise size of these bands is unknown because
covalently cross-linked proteins migrate anomalously on SDS-PAGE
and, in addition, there were no standards for molecular masses
> 200 kDa. It was clear, however, that the complexes consisted of a
doublet band > 200 kDa and, more variably, a single band µ200 kDa.
As a control, samples of fibroblast conditioned medium (Fig 1, CM)
were also immunoblotted with anti-MMP-1. ProMMP-1 was observed
to migrate as a broad single band that often could be resolved into a
doublet of 52–54 kDa (a result of differential glycosylation) (see also
Fig 6). In other controls, we found that MMP-1 was undetectable in
three different samples of mastectomy fluid collected at days 1–2 after
surgery (Fig 1, MF), or in plasma (data not shown).
The concentration of the MMP-1 containing complexes in wound
fluid was quite low and difficult to estimate. The protein concentration
of burn wound fluid ranges from 30 to 50 mg per ml, and the overall
protein profile of burn fluid resembles plasma (Young and Grinnell,
1994). In Fig 1, it was not possible to load more than 75 µg of protein
(µ2 µl burn fluid) per lane; higher amounts distorted the electrophoretic
profile. At this protein concentration, however, no detectable protein
stained bands appeared to correspond to the MMP-1 complexes
(see Fig 5).
The above findings suggested that proMMP-1 was released into the
wound environment within the first few days after injury, and
subsequently formed high molecular mass, covalently cross-linked
complexes. Because these complexes might have been unique to the
burn wound environment, similar studies were carried out using
wound fluid samples from five patients with venous stasis ulcers.
Figure 2 shows that wound fluid samples from four of the five patients
contained the . 200 kDa doublet MMP-1 complexes. In several of
the wound fluid samples (#1–2, #2–3, and #1–4), immunoreactive
proMMP-1 bands were also evident.
High molecular mass MMP-1 containing complexes also contain
a2M In plasma, α2M is the major inhibitor of collagenase (Eisen
et al, 1970; Werb et al, 1974), and purified MMP-1 and α2M have
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Figure 3. Burn fluid contains α2M and α2M cleavage products (CP).
Samples of plasma (P, 6 µg), burn fluid (BF, 6 µg) collected from three different
patients on the days indicated following injury, and mastectomy fluid (MF,
6 µg), were subjected to SDS-PAGE and immunoblotted with antibodies
against α2M.
Figure 4. Chronic wound fluid contains a2M and a2M cleavage
products. Samples of chronic wound fluid (CF, 6 µg) collected from five
different patients at weekly intervals as indicated, were subjected to SDS-PAGE
and immunoblotted with antibodies against α2M.
been shown to form high molecular mass covalent complexes in vitro
(Sottrup-Jensen and Birdedal-Hansen, 1989). Therefore, the complexes
described in Figs 1 and 2 might have resulted from binding between
MMP-1 and α2M. To learn more about the possible role of α2M in
the formation of MMP-1 complexes, burn fluid and chronic wound
fluid samples were also immunoblotted with polyclonal antibodies
against α2M.
Figure 3 shows that the level of α2M (detected as the 185 kDa
subunit) in burn fluid or mastectomy fluid (MF) was only slightly less
than that observed in plasma (P). Burn fluid and mastectomy fluid also
contained increased α2M cleavage peptide bands (CP) (100/85 kDa)
compared with plasma, indicating that in both cases local interactions
had occurred between activated proteinases and α2M. Figure 4 shows
comparable results with chronic wound fluid, i.e., the presence of both
α2M and α2M cleavage peptide bands. The , 85 kDa α2M cleavage
peptides in several wound fluid samples (#2–1, 3–3, and 5–1) is
characteristic of wound fluids with elevated elastase activity (Grinnell
and Zhu, 1996).
The presence of plasma levels of α2M in burn fluid and chronic
wound fluid was consistent with the possibility that α2M regulates
collagenase activity in the wound environment and was responsible
for the MMP-1 complexes shown in Figs 1 and 2. If so, then why
were there no corresponding high molecular mass bands detected in
Figs 3 and 4 in the anti-α2M immunoblots? One possible explanation
for the lack of α2M staining of the high molecular mass complexes
was a change in immunoreactivity as a result of complex formation,
and the complexes were also undetectable with a different polyclonal
antibody (Dako, Carpinteria, CA; data not shown). It was also possible,
however, that the anti-α2M immunoblots were not sensitive enough
to detect the small quantities of complex that occurred in wound fluid.
Figure 5. MMP-1 containing complexes are cleared from wound fluid
after treatment with anti-a2M coated beads. Protein A-Sepharose CL-4B
beads (30 µl) were incubated for 30 min at 4°C with 180 µl Dulbecco’s
phosphate buffered saline (150 mM NaCl, 3 mM KCl, 1 mM CaCl2, 0.5 mM
MgCl2, 1 mM KH2PO4, 6 mM Na2HPO4, pH 7.2) with or without 0.13 mg
anti-α2M. The antibody coated beads (‘‘1’’ lanes) and control beads (‘‘–’’ lanes)
were then washed three times with phosphate buffered saline (150 mM NaCl,
3 mM KCl, 1 mM KH2PO4, 6 mM Na2HPO4, pH 7.2)/0.1% bovine serum
albumin and incubated overnight at 4oC with 500 µg samples of burn fluid or
chronic wound fluid (1, CF#1–2; 2, BF#5–2-4; 3, BF#5–4-4). The mixtures
were centrifuged at 4oC for 30 s at 5000 rpm (Beckman microfuge), and
aliquots of the supernatants were subjected to SDS-PAGE and immunoblotted
with antibodies against α2M (left panel) or MMP-1 (right panel), or stained with
coomassie blue (CB) (center panel).
If this were the case, we predicted that the complexes would be
removed from wound fluid with anti-α2M antibody-coated beads.
Figure 5 describes experiments that tested the ability of anti-α2M
coated beads to remove MMP-1 containing complexes from wound
fluid. As shown in the left panel, anti-α2M coated beads (1) but not
control beads (–) removed most of the α2M and the cleavage peptides
(CP) from wound fluid. These treatments did not, however, change
the overall coomassie blue protein profiles of the samples (center
panel), except for a decrease in a polypeptide band that corresponded
to α2M. The right panel shows that clearing the samples with anti-
α2M coated beads also removed the MMP-1 containing complexes
(MMP-1*), but had no effect on proMMP-1. The ability of anti-α2M
to selectively remove MMP-1 containing complexes from wound fluid
provides direct evidence that the complexes contained both α2M and
MMP-1.
Formation of high molecular mass MMP-1 complexes occurs
in vitro upon mixing of human serum and fibroblast
conditioned medium Although several factors might contribute
to complex formation, the simplest explanation for the results
described in Figs 1–5 was that plasma α2M in the wound environ-
ment combined with locally synthesized/activated MMP-1 to form
covalent MMP-1/α2M complexes. If this were the case, then similar
complexes would be expected to form after mixing human serum with
conditioned medium containing activated MMP-1.
Figure 6 presents typical results of such a mixing experiment. As
shown in the left panel (immunoblotted with anti-MMP-1), formation
of high molecular mass MMP-1 containing complexes (µ200 kDa and
.200 kDa doublet) occurred if conditioned medium was mixed with
serum and then proMMP-1 was activated by APMA (CM 1 SERUM
1 APMA). These complexes did not form in the absence of MMP
activation (CM 1 SERUM), or if conditioned medium was activated
with APMA prior to mixing with serum (CM 1 APMA 1 SERUM)
(see Fig 8). Therefore, formation of the complexes requires both
proMMP-1 activation and the presence of serum component(s) at the
time of activation. As shown in the right panel (immunoblotted with
anti-α2M), there was a slight increase in the α2M cleavage peptide
bands under conditions that favored complex formation (CM 1
SERUM 1 APMA). These immunoblots were overdeveloped, which
made it possible to detect faint bands that might have corresponded to
the high molecular mass MMP-1 containing complexes.
As an additional test of the dependence of complex formation on
α2M, serum samples were immunoadsorbed using beads coated with
(1) or without (–) anti-α2M, and then the supernatants were used in
mixing experiments. Figure 7 (left panel) shows that α2M in starting
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Figure 6. Activation of MMP-1 in the presence of serum results in the
formation of cross-linked MMP-1 complexes. CM 1 APMA 1 SERUM,
samples of fibroblast condition medium (CM, 40 µl) were incubated with
APMA for 1 h and then mixed with serum (150 µg) for 30 min; CM 1
SERUM, same as CM 1 APMA 1 SERUM except CM was incubated with
serum for 60 min in the absence of APMA; CM 1 SERUM 1 APMA, same
as CM 1 APMA 1 SERUM except CM was incubated with serum for 3 min
and then APMA for an additional 60 min. The reactions were terminated by
addition of SDS-sample buffer, and aliquots were subjected to SDS-PAGE and
immunoblotted with antibodies against MMP-1 or α2M.
Figure 7. Serum depleted of a2M cannot form cross-linked MMP-1
complexes. Protein A-Sepharose CL-4B beads (100 µl) were incubated for
30 min at 4°C with 180 µl Dulbecco’s phosphate buffered saline with or
without 0.26 mg anti-α2M. The antibody coated beads (‘‘1’’ lanes) and control
beads (‘‘–’’ lanes) were then washed three times with PBS/0.1% bovine serum
albumin and incubated overnight at 4°C with human serum (100 µl, 54 mg
per ml). The mixtures were centrifuged at 4°C for 30 s at 5000 rpm (Beckman
microfuge). Final protein concentration of the supernatant fractions was µ21 mg
per ml. Left and center panels, aliquots of starting serum (S) and supernatants
(super) were subjected to SDS-PAGE and immunoblotted with antibodies
against α2M (sample 5 6 ug per lane) or with coomassie blue (CB, sample 5
75 µg per lane). Left panel, samples of serum (150 µg) or supernatant fractions
(150 µg) were incubated with conditioned medium (C, 40 µl) as indicated and
then APMA for 60 min. The reactions were terminated by the addition of
SDS-sample buffer, and aliquots were subjected to SDS-PAGE and
immunoblotted with antibodies against MMP-1.
serum (S) was completely removed by anti- α2M coated beads (1),
but not by control beads (–). Figure 7 (center panel) shows that the
overall coomassie blue (CB) protein profile of serum (S) was unchanged
by adsorption except for the α2M band. Figure 7 (right panel) shows
that mixing serum (S) or the supernatant from the control beads (–)
with activated fibroblast conditioned medium resulted in formation of
the MMP-1 complexes (MMP-1*). These complexes were undetect-
able (even though the immunoblots were overdeveloped) when
supernatant from serum adsorbed with anti- α2M beads (1) was mixed
Figure 8. Activation of MMP-1 in the absence of serum results in
formation of TIMP-1/MMP-1 complexes. Fibroblast conditioned medium
(280 µl) was incubated with APMA for the times indicated. The reactions were
terminated by addition of nonreducing SDS-sample (62.5 mm Tris, 2% SDS,
10% glycerol, 0.01% bromophenol blue, pH 6.8). Aliquots of the samples were
subjected to SDS-PAGE (10% acrylamide gels) and immunoblotted with
antibodies against MMP-1 and TIMP-1.
with activated MMP-1. Therefore, formation of all three high molecular
mass complex bands (µ200 kDa and .200 kDa doublet) required the
presence of α2M.
Activation of MMP-1 in the absence of a2M inhibits forma-
tion of high molecular mass complexes Finally, additional experi-
ments were carried out to clarify the finding shown in Fig 6 that
MMP-1 containing complexes did not form if proMMP-1 was
activated with APMA first and then mixed with serum afterwards (CM
1 APMA 1 SERUM versus CM 1 SERUM 1 APMA). It has been
reported that formation of MMP-1/TIMP-1 complexes prevents
subsequent binding of MMP-1 to α2M (Windsor et al, 1994). Because
fibroblast culture medium contains TIMP-1 (Stricklin and Welgus,
1983), activation of proMMP-1 in conditioned medium may have
resulted in the formation of such complexes. To test this point,
conditioned medium was incubated with APMA for various times.
Then the samples were subjected to SDS-gel electrophoresis in the
absence of reducing reagent because MMP/TIMP complexes are SDS-
stable under these conditions (DeClerck et al, 1989).
Figure 8 (lower panel) shows that fibroblast conditioned medium
contained a prominent 28 kDa TIMP-1 band. When conditioned
medium was incubated with APMA, there was a time dependent
appearance beginning around 10 min of a µ66 kDa TIMP-1 contain-
ing complex. Figure 8 (upper panel) shows that the µ66 kDa band
also contained MMP-1. Thus, incubation of conditioned medium
with APMA resulted in formation of SDS-stable MMP-1/TIMP-1
complexes under conditions that prevented the formation of MMP-
1/α2M complexes.
DISCUSSION
The purpose of this study was to examine the appearance and activation
of MMP-1 in the wound environment. We found that MMP-1
accumulates in the fluid phase of the burn wound environment within
2 d of injury and reaches maximal levels by day 4. Two forms of the
enzyme were evident, one that corresponded to proMMP-1 and
another that corresponded to a group of MMP-1 containing complexes
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(µ200 kDa and .200 kDa doublet). Wound fluid from venous stasis
ulcers also contained proMMP-1 and MMP-1 containing complexes,
although to a more variable extent than in burn fluid. The absence of
MMP-1 and its complexes from mastectomy fluid may have
resulted from the early time period of collection (day 1–2) or
the method of collection, i.e., under pressure, which reduces the
concentration of locally produced molecules relative to the plasma
ultrafiltrate.
Beginning with the work of Eisen et al (1970) and Werb et al (1974),
it has become evident that α2M can bind and sequester activated
MMP-1, resulting in the formation of inactive complexes (Birkedal-
Hansen et al, 1993). The chemical nature of the covalent complexes
results in 1:1 stoichiometry between activated MMP-1 molecules and
α2M subunits (185 kDa) (Sottrup-Jensen and Birkedal-Hansen, 1989;
Windsor et al, 1994; Nagase et al, 1994), similar to other proteinase/
α2M combinations (e.g., Wang et al, 1984; Feinman, 1994). Details
regarding formation of larger complexes involving dimers or tetramers
remain somewhat controversial, however (Chen et al, 1992b). In any
case, it seems likely that the µ200 kDa band observed in wound fluid
represents binding between a single MMP-1 molecule and a α2M
subunit. Composition of the .200 kDa doublet remains to be
determined. The low concentration of complexes in wound fluid and
the limited amounts of wound fluid available have precluded the
possibility of direct isolation and characterization of the complexes.
It is unclear why in burn or chronic ulcer wound fluid, the .200 kDa
doublet was usually more prominent than the µ200 kDa complex;
whereas the µ200 kDa component was more prominent after de novo
formation of the complexes by mixing serum with APMA activated
conditioned medium. One possible explanation for these findings is
that the µ200 kDa complex turns over more rapidly in tissue than
does the .200 kDa doublet. Although clearance of α2M-proteinase
complexes in the blood has been studied in great detail, relatively little
is known about clearance in extravascular spaces such as the wound
environment (Borth, 1992; Petersen, 1993).
The mechanisms that regulate metalloproteinases in the wound
environment depend on several factors, including the number and cell
types that migrate into the wound region, transcriptional activation of
MMP genes by resident cells, extracellular activation of secreted
proenzymes, and local concentration of TIMP and plasma proteinase
inhibitors (Alexander and Werb, 1991; Woessner, 1991; Matrisian,
1992; Birkedal-Hansen et al, 1993; Vincenti et al, 1996; Edwards
et al, 1996; Cawston, 1996). Our data demonstrating the presence of
α2M/MMP-1 complexes in wound fluid suggest that α2M regulates
MMP-1 activity in the tissue environment during wound repair.
Several in vivo and in vitro studies have implicated MMP-1 in epidermal
migration (e.g., Saarialho-Kere et al, 1993; Inoue et al, 1995; Pilcher
et al, 1997). In the case of migration, MMP-1 probably acts locally
where the cell surface interacts with the extracellular matrix. Once
collagenase or other enzymes reach the fluid phase of the wound
environment, however, they would become targets for sequestration
by α2M.
Although it has been reported that α2M regulates MMP-1 in
arthritic joints (c.f., Abe and Nagai, 1973), and the level of α2M in
synovial fluid approaches 30% of that in serum (Cawston et al, 1987),
TIMP rather than α2M are generally believed to be the primary
mechanism for regulating MMP-1 in the extravascular space. It has
usually been assumed that α2M levels in the extravascular space would
be low because the molecule is so large (c.f. Vincenti et al, 1996);
nevertheless, we found that α2M levels in burn wound fluid and
chronic ulcer wound fluid were almost as high as in plasma. Moreover,
we showed previously that α2M plays a critical role in inhibiting
elastase activity in chronic wounds (Grinnell and Zhu, 1996). Taken
together, our findings support the idea that α2M plays a general role
in regulating proteinases in the extracellular matrix as well as in
intravascular space (Enghild et al, 1989; Sottrup-Jensen and Birkedal-
Hansen, 1992).
Based on in vitro binding data, it has been proposed that MMP-1
binds preferentially to α2M compared with TIMP-1 (Cawston and
Mercer, 1986). Our data support this idea. Consistent with previous
studies, we found that binding of MMP-1 to TIMP-1 prevented the
formation of MMP-1/α2M complexes when conditioned medium
was treated with APMA in the absence of serum (see also Windsor
et al, 1994). Moreover, MMP-1/TIMP-1 complexes were rare in burn
fluid or chronic wound fluid; otherwise, they would have dissociated,
producing an MMP-1 band under reducing SDS-PAGE conditions.
Although TIMP-1 synthesis in the dermis and epidermis has been
demonstrated following wounding (Stricklin et al, 1994; Vaalamo et al,
1996), and TIMP-1 levels have been reported to increase rapidly in
acute wound fluid (Bullen et al, 1995), much of the inhibitor may be
bound to other MMP, such as MMP-9 or stromelysin-1, or may
function in processes unrelated to inhibition of MMP activity (Edwards
et al, 1996).
The low level of interstitial collagenase in chronic wound fluid was
unexpected. Based on immunolocalization and in situ hybridization
studies (Saarialho-Kere et al, 1993. 1995; Inoue et al, 1995; Vaalamo
et al, 1996), one would have anticipated that MMP-1 levels in chronic
wound fluid should at least equal those in burn wound fluid. One
could argue that fluid phase MMP-1 only accounts for a small portion
of total MMP-1, much of which may be bound to extracellular matrix
and recovered only by rigorous extraction methods (Agren et al, 1992).
But the timing of the appearance of MMP-1 in the fluid phase
correlates well with the appearance of MMP-1 in the tissue (Stricklin
and Nanney, 1994; Vaalamo et al, 1996). Alternatively, MMP-1 and
its complexes may turn over faster in the fluid phase than in tissues,
especially in chronic wounds. With levels of TIMP-1 decreased in
chronic wounds (Bullen et al, 1995; Vaalamo et al, 1996), formation
of α2M/MMP-1 complexes may become the preferential mechanism
of MMP clearance. Direct measurement of type I collagen digestion
has shown that some enzyme activity can be detected in acute and
chronic wound fluid, but there is not yet agreement on the type of
collagenase responsible or on the possible differences between chronic
and acute wounds (Yager et al, 1996; Weckroth et al, 1996).
Combined with our previous studies (Young and Grinnell, 1994),
the data on MMP-1 appearance and activation provide a coordinated
picture of MMP metabolism in the fluid phase of the acute wound
environment. Initially, within 4–8 h, gelatinase proMMP-9 appears,
consistent with neutrophils as the initial source of this enzyme (Hibbs
et al, 1985; Vartio and Hovi, 1987). In addition to MMP-1, gelatinase
A (proMMP-2) appears around day 2, presumably derived from stromal
cells (Murphy et al, 1989). Finally, stromelysin proMMP-3 appears
around day 4. By day 4, all the MMP have reached their maximal
levels and enzyme activation has occurred. Regulation of MMP-1
activity may depend on α2M, and MMP-2 and MMP-9 on TIMP.
We suggest that these events comprise the tissue’s normal debridement
mechanism, which becomes unbalanced in chronic wounds.
This research was supported by NIH grant GM21681. We are indebted to Dr. Patty
Young for collecting burn wound fluid samples.
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